1
|
Cescon DW. Abstract ES13-3: Novel epigenomic targets in TNBC. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-es13-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancer is a heterogenous disease, characterized by a dearth of recurrent actionable genetic alterations. Epigenetic alterations have been implicated in the pathogenesis of triple negative breast cancer, as well as in the acquisition of drug resistance, which is a commonly observed phenomenon and persisting clinical challenge. An expanding array of tools for epigenomic characterization, together with novel selective inhibitors of epigenetic regulators are enabling new opportunities to identify and target these processes in triple negative breast cancer. Examples of recent and emerging therapeutic strategies using conventional therapies and epigenetic-targeted agents to exploit these vulnerabilities in triple negative breast cancer will be discussed.
Citation Format: DW Cescon. Novel epigenomic targets in TNBC [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES13-3.
Collapse
Affiliation(s)
- DW Cescon
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| |
Collapse
|
2
|
Cescon D. Accelerating progress from advanced to early breast cancer (SERDS, PI3Kinhibitors, other novel agents). Breast 2021. [DOI: 10.1016/s0960-9776(21)00056-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
3
|
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2020; 30:397-404. [PMID: 30475950 DOI: 10.1093/annonc/mdy517] [Citation(s) in RCA: 488] [Impact Index Per Article: 122.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival. RESULTS All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs. CONCLUSIONS Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02447003.
Collapse
Affiliation(s)
- S Adams
- Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA.
| | - P Schmid
- Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK
| | - H S Rugo
- Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - E P Winer
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - A Awada
- Oncology Medicine Departmen, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
| | - D W Cescon
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Campone
- Institut de Cancerologie de l'Ouest, Nantes, France
| | - R Nanda
- Department of Medicin, Section of Hematology/Oncology, The University of Chicago, Chicago, USA
| | - R Hui
- Westmead Hospital and the University of Sydney, Sydney, Australia
| | - G Curigliano
- Department of Oncology and Hematology, University of Milano, Milan; IEO, European Institute of Oncology IRCCS, Milano, Milan, Italy
| | - D Toppmeyer
- Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA
| | - J O'Shaughnessy
- Baylor University Medical Center, Dallas; Texas Oncology, Dallas; US Oncology, Dallas, USA
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S Paluch-Shimon
- Breast Cancer Service for Young Women, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - A R Tan
- Levine Cancer Institute, Atrium Health, Charlotte
| | - D Card
- Merck & Co., Inc., Kenilworth, USA
| | - J Zhao
- Merck & Co., Inc., Kenilworth, USA
| | | | - J Cortés
- Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona; Ramon y Cajal University Hospital, Madrid; IOB Institute of Oncology, Quiron Group, Barcelona, Spain
| |
Collapse
|
4
|
Keilty D, Namini SN, Swain M, Maganti M, Cil T, McCready D, Cescon D, Amir E, Fleming R, Mulligan A, Levin W, Liu F, Croke J, Fyles A, Koch C, Han K. Predictors of Survival and Patterns of Recurrence in Breast Cancer Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Veitch ZW, Bedard P, Tang PA, Conway JL, Ribnikar D, Albaba H, King K, Lupichuk S, Cescon D. Abstract P6-17-29: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Veitch ZW, Bedard P, Tang PA, Conway JL, Ribnikar D, Albaba H, King K, Lupichuk S, Cescon D. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-29.
Collapse
Affiliation(s)
- ZW Veitch
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - P Bedard
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - PA Tang
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - JL Conway
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - D Ribnikar
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - H Albaba
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - K King
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - S Lupichuk
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| | - D Cescon
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Princess Margaret Cancer Centre, University of Toronto, Edmonton, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
6
|
Goodwin PJ, Ennis M, Cescon DW, Elser C, Haq R, Hamm CM, Lohmann AE, Pimentel I, Chang MC, Dowling RJ, Stambolic V. Abstract P1-16-03: Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breast cancer (MBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-16-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: MET treatment of diabetes is associated with improved BC outcomes. Hirsch et al (Cancer Res 2009;69:7505-7511) suggested MET may act synergistically with CXT in BC rodent models. We conducted a double-blind Phase II RCT of CXT plus MET vs placebo in LABC/MBC.
Methods: Non-diabetic BC patients (pts) about to commence 1st-4th line CXT (prespecified anthracycline, taxane, vinorelbine, platinum or capecitabine; HER2 Rx permitted) for MBC or refractory LABC (any ER, PgR, HER2) were eligible if (i) age 18-75, (ii) ECOG 0-2, (iii) adequate hepatic, renal, bone marrow, cardiac function and (iv) measurable or evaluable disease. Those with CNS metastases, recent MET use or radiotherapy to target lesions, intake of ≥ 3 alcoholic drinks/day, history of lactic acidosis or current/planned pregnancy or lactation were ineligible. Randomization was to MET 850 mg po bid (or identical PLAC bid) with a 2 day ramp up of one tablet/day; dose was reduced/drug discontinued in a pre-specified manner for grade 2-4 toxicity. Disease status and toxicity/HRQOL were assessed at baseline and q9 weeks until progression. Primary outcome was progression-free survival (PFS); secondary outcomes included survival (OS), response and toxicity. With 40 subjects and type one error 0.2 (1-sided), a PFS HR of 0.58 could be detected with 80% power. PFS was analyzed using Cox proportional hazards regression.
Results: 40 pts were randomized (22 MET, 18 PLAC). Mean age 55.4 vs 56.9 years; ER/PgR+ in 86.4 vs 83.3%; time from 1st metastases to randomization 297 vs 405 days, in MET vs PLAC respectively. MET pts were more likely to have visceral metastases (95.5% vs 72.2% PLAC) and less likely to be HER2+ (9.1% vs 23.5% PLAC). CXT was 1st line in 68.2% MET and 66.7% PLAC pts. Toxicity - # events: Gr 4: 0 MET vs 1 PLAC, Gr 3: 14 MET vs 14 PLAC; Gr 1 or 2: 193 MET (mainly GI) vs 53 PLAC. Best response: PR 18.2% MET vs 22.2% PLAC, SD 31.8% MET vs 11.1% PLAC, PD 45.4% MET vs 50.0% PLAC, P = 0.41. Mean PFS 164 days MET vs 192 days PLAC; HR (MET vs PLAC) 1.14 (95% CI 0.59-2.2), 1-sided p=0.65. Mean OS 645 MET vs 831 PLAC days; HR (MET vs PLAC) 1.6, 95% CI 0.72-3.54, 1-sided p=0.88.
Conclusion: In these BC pts receiving 1st-4th line CXT, MET (vs PLAC) did not improve response rates, PFS or OS. Gr 1 and 2 toxicity was higher with MET than PLAC. These results do not support use of MET with CXT in refractory LABC/MET BC. MA32, an adjuvant trial of MET vs PLAC in early BC will provide information on MET in the adjuvant setting.
Funded by the Breast Cancer Research Foundation (New York) and Hold'em for Life Charity (Toronto)
Citation Format: Goodwin PJ, Ennis M, Cescon DW, Elser C, Haq R, Hamm CM, Lohmann AE, Pimentel I, Chang MC, Dowling RJ, Stambolic V. Phase II randomized clinical trial (RCT) of metformin (MET) vs placebo (PLAC) in combination with chemotherapy (CXT) in refractory locally advanced (LABC) or metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-16-03.
Collapse
Affiliation(s)
- PJ Goodwin
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - M Ennis
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - DW Cescon
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - C Elser
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - R Haq
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - CM Hamm
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - AE Lohmann
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - I Pimentel
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - MC Chang
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - RJ Dowling
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| | - V Stambolic
- Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; Applied Statistician, Markham, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; St. Michael's Hospital, Toronto, Canada; Windsor Regional Cancer Center, Windsor, Canada; Sinai Health System, Toronto, Canada; University of Toronto, Toronto, Canada
| |
Collapse
|
7
|
Jerzak KJ, Cescon DW, Chia SK, Bratman S, Ennis M, Stambolic V, Chang M, Dowling R, Goodwin PJ. Abstract OT1-12-01: Exploration of factors associated with imminent risk of late recurrence in hormone receptor positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Research objectives: To conduct a prospective observational study of patient and tumor-related factors in women with high risk hormone receptor (HR)+/HER2- breast cancer (BC) following at least 5 years of adjuvant hormonal therapy, in order to identify risk factors for imminent recurrence.
Rationale: Many of the life-threatening BC recurrences in women with HR+HER2- BC take place more than 5 years post-diagnosis, often after completion of adjuvant hormonal therapy. The identification of a biomarker(s) for late BC recurrence could lead to interventional trials to evaluate preventive therapies. We will evaluate whether the presence of blood-based biomarkers [(i) Circulating Tumor Cells (CTCs), (ii) circulating tumor DNA (ctDNA), (iii) tumor markers (CA 15-3, CEA)] and patient factors may predict BC recurrence.
Trial design: A prospective cohort of eligible women with previously treated HR+HER2- BC who have not experienced a distant recurrence will be enrolled; patient and circulating factors will be measured annually until distant recurrence or study completion. Host factors (including BMI, lifestyle, medical illness, surgery, trauma and stress, as well as circulating PlGF, VEGF-1 and inflammatory markers) that may contribute to exit of BC cells from dormancy will also be assessed.
The primary outcome is distant BC recurrence. Any BC event, including loco-regional recurrence, new breast or other primary cancer will be evaluated as a secondary endpoint. Outcomes will be ascertained by regular self-report (via annual telephone calls) and/or physician report and confirmed by medical record review.
Key eligibility criteria: i) Diagnosis of ER and/or PR positive (either or both 10% positive), HER2 negative invasive BC, ii) predicted >1.5-2% annual risk of recurrence (T2, T3 or T4 with any N+;T1 N2+; T2N0 or T1 N1 cancers with high risk genomic scores), iii) receipt of adjuvant endocrine therapy for at least 4 years, with discontinuation planned in the next 12 months or completion of endocrine therapy within the last 5 years, iv) prior adjuvant chemotherapy, targeted therapy and bone targeted therapies are allowed provided they have been completed.
Specific aims: 1) Determine if the presence of (i) CTCs, (ii) ctDNA, (iii) CA15-3 and CEA are associated with imminent risk (within 1-2 years) of distant recurrence in the study population. 2) Identify host factors associated with these blood-based biomarkers, as well as clinical outcomes.
Statistical methods: A matched case control design (matching for time since completion of adjuvant hormone therapy, baseline T, N and grade) will be used to investigate associations of key study variables with imminent risk of distant recurrence within the next 1-2 years. Measurements of patients who do versus do not recur will be compared over the 1-2 years prior to relapse. Each variable will be allocated one third of a study-wide type one error of 0.05 (2-sided). ROC analyses and multivariable modelling will be used to optimize sensitivity, specificity, PPV and NPV. Available questionnaire data will be summarized at all time-points to generate descriptive survivorship data.
Accrual: Starting in August 2018, we plan to recruit 1,000 patients over 2 years at selected Canadian cancer centres.
Citation Format: Jerzak KJ, Cescon DW, Chia SK, Bratman S, Ennis M, Stambolic V, Chang M, Dowling R, Goodwin PJ. Exploration of factors associated with imminent risk of late recurrence in hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-12-01.
Collapse
Affiliation(s)
- KJ Jerzak
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - DW Cescon
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - SK Chia
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - S Bratman
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - M Chang
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - R Dowling
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre Research Institute, University of Toronto, Toronto, ON, Canada; Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada; Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
8
|
Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H, Telli M, Loi S, Cortés J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Tryfonidis K, Karantza V. Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot3-04-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Although ER+/HER2– breast cancer has a better overall prognosis than other breast cancer subtypes, there is a high-risk subpopulation characterized by high-grade tumors and decreased sensitivity to endocrine therapy, higher responsiveness to chemotherapy and worse prognosis. A large meta-analysis of prospective studies focusing on neoadjuvant chemotherapy (NAC) for treatment of stage I-III breast cancer demonstrated that increased pathologic complete response (pCR) rates at surgery were associated with improved survival. This correlation was observed across triple-negative breast cancer (TNBC), HER2+ breast cancer, and high-grade HR+/HER2- breast cancer. Specifically, patients with a pCR after NAC had a 5-year event-free survival (EFS) rate of 90%, whereas patients who did not achieve a pCR had a 5-year EFS rate of 60%.Therefore, increasing pCR rates after NAC may have a substantial impact for patients with high-risk early-stage HR+/HER2– breast cancer. KEYNOTE-756 is a global, randomized, double-blind, phase III study of pembrolizumab (vs placebo) + chemotherapy as neoadjuvant treatment, followed by pembrolizumab (vs placebo) plus endocrine therapy as adjuvant treatment for patients with high-risk, early-stage ER+/HER2– breast cancer.
Methods: Patients with T1c-2 cN1-2 or T3-4 cN0-2 grade 3 or grade 2 with Ki-67 ≥30%, invasive, ductal ER+/HER2– breast cancerwill be stratified by lymph node involvement (positive vs negative), tumor PD-L1 status (positive vs negative), ER positivity (≥10% vs <10%), and anthracycline dosing schedule (Q3W vs Q2W), and then randomized 1:1 to receive neoadjuvant treatment with pembrolizumab 200 mg Q3W or placebo in combination with paclitaxel (80 mg/m2 QW) for 4 cycles followed by (doxorubicin [60 mg/m2] or epirubicin [100 mg/m2]) plus cyclophosphamide (600 mg/m2) Q2/3W for another 4 cycles. After definitive surgery (± radiation therapy, as indicated), patients will receive adjuvant treatment with pembrolizumab (200 mg Q3W) or placebo for 9 additional administrations, in combination with endocrine therapy, which can be given for up to 10 years. Co-primary end points are pCR rate and EFS. Secondary end points are safety and overall survival. The global study will open in North America and Latin America, Europe, and Asia Pacific in the second half of 2018.
Citation Format: Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H, Telli M, Loi S, Cortés J, Schmid P, Harbeck N, Denkert C, Jackisch C, Jia L, Tryfonidis K, Karantza V. KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-04-03.
Collapse
Affiliation(s)
- F Cardoso
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - A Bardia
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - F Andre
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - DW Cescon
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - H McArthur
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - M Telli
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - S Loi
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - J Cortés
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - P Schmid
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - N Harbeck
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - C Denkert
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - C Jackisch
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - L Jia
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - K Tryfonidis
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| | - V Karantza
- Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Massachusetts General Hospital, Harvard Medical School, Boston, MA; Faculté de Medicine Paris-Sud XI, Gustave Roussy, Paris, France; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Cedars-Sinai Medical Center, Los Angeles, CA; Stanford University School of Medicine, Stanford, CA; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; Breast Cancer Program, Ramon y Cajal University Hospital, Madrid, Spain; Centre for Experimental Medicine, Barts Cancer Institute, London, United Kingdom; Breast Center, Ludwig-Maximilian University of Munich, Munich, Germany; Institute of Pathology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Sana Klinikum, Offenbach, Germany; Merck & Co., Inc., Kenilworth, NJ
| |
Collapse
|
9
|
Abstract
Deregulation of the cell cycle is a hallmark of cancer that enables limitless cell division. To support this malignant phenotype, cells acquire molecular alterations that abrogate or bypass control mechanisms in signaling pathways and cellular checkpoints that normally function to prevent genomic instability and uncontrolled cell proliferation. Consequently, therapeutic targeting of the cell cycle has long been viewed as a promising anti-cancer strategy. Until recently, attempts to target the cell cycle for cancer therapy using selective inhibitors have proven unsuccessful due to intolerable toxicities and a lack of target specificity. However, improvements in our understanding of malignant cell-specific vulnerabilities has revealed a therapeutic window for preferential targeting of the cell cycle in cancer cells, and has led to the development of agents now in the clinic. In this review, we discuss the latest generation of cell cycle targeting anti-cancer agents for breast cancer, including approved CDK4/6 inhibitors, and investigational TTK and PLK4 inhibitors that are currently in clinical trials. In recognition of the emerging population of ER+ breast cancers with acquired resistance to CDK4/6 inhibitors we suggest new therapeutic avenues to treat these patients. We also offer our perspective on the direction of future research to address the problem of drug resistance, and discuss the mechanistic insights required for the successful implementation of these strategies.
Collapse
Affiliation(s)
- K L Thu
- a Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada
| | - I Soria-Bretones
- a Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada
| | - T W Mak
- a Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada.,b Department of Medical Biophysics , University Health Network , Toronto , Canada
| | - D W Cescon
- a Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada.,c Department of Medicine , University of Toronto , Toronto , Canada
| |
Collapse
|
10
|
Pluard T, Oh SY, Oliveira M, Cescon D, Tan-Chiu E, Wu Y, Carpenter C, Cunningham E, Ballas M, Dhar A, Sparano J. Abstract OT3-06-07: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-06-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Advanced or metastatic ER+BC (estrogen receptor positive breast cancer) is an incurable illness that will prove fatal for most afflicted women. Current standards of care include endocrine, targeted, and chemotherapy. Preclinical data suggest that altering the expression of the estrogen receptor (ER) as well as other ER-responsive genes may provide therapeutic benefit for women for whom endocrine therapy alone has proven inadequate. The bromodomain (BRD) and extra-terminal (BET) family of proteins (BRD2, BRD3, BRD4 and BRDT) bind to acetyl-histone residues and epigenetically control transcription of genes driving cell survival and proliferation. BET proteins have been implicated in carcinogenesis and treatment resistance in multiple tumors including ER+BC, and are a novel target for therapy in breast cancer. GSK525762 is a pan-BET inhibitor that has shown strong synergistic activity with fulvestrant in killing ER+BC cells in vitro and in xenograft models. The combination of BET agents with endocrine therapy may provide therapeutic benefit and restore sensitivity to ER targeting agents like fulvestrant.
Trial Design & Specific Aims:
This study is a Phase I/II dose-escalation, expansion (Phase I) and randomized control (Phase II) study with oral administration of GSK525762 in combination with fulvestrant in advanced or metastatic ER+BC subjects, whose disease has progressed on prior treatment with at least one line of endocrine therapy.
Phase I of the study is designed as parallel single arms to determine a recommended Phase 2 dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles in two distinct populations of ER+ breast cancer:
Subjects with disease that relapsed during treatment or within 12 months of adjuvant therapy with an AI, OR disease that progressed during treatment with an AI for advanced/metastatic disease.
OR
Subjects with disease that progressed during treatment with the combination of a CDK4/6 inhibitor plus letrozole for advanced or metastatic disease.
Phase II of the study is a randomized, double-blind, placebo-controlled cohort, designed to evaluate the efficacy of the combination.
Key Eligibility Criteria: Patients must have received <3 lines of systemic anti-cancer therapy (≤1 line of chemo), measurable disease, and PS 0-1.
Statistical Methods: A modified toxicity probability interval (mTPI) design will be used to monitor safety. A Bayesian adaptive design will be used to evaluate efficacy in Phase 1.
Present and Target Accrual: Target enrolment will be ˜300 subjects across ˜50 sites worldwide. To date, 2 subjects have been enrolled.
Contact Information: Elizabeth Cunningham, Elizabeth.A.Cunningham@GSK.com.
NCT02964507
Funding: GSK
Citation Format: Pluard T, Oh SY, Oliveira M, Cescon D, Tan-Chiu E, Wu Y, Carpenter C, Cunningham E, Ballas M, Dhar A, Sparano J. A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-06-07.
Collapse
Affiliation(s)
- T Pluard
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - SY Oh
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - M Oliveira
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - D Cescon
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - E Tan-Chiu
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - Y Wu
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - C Carpenter
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - E Cunningham
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - M Ballas
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - A Dhar
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| | - J Sparano
- St. Luke's Cancer Institute, Kansas City, MO; Montefiore-Einstein Cancer Center, Bronx, NY; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; Florida Cancer Research Institute, Plantation, FL; GlaxoSmithKline, Collegeville, PA
| |
Collapse
|
11
|
Stjepanovic N, Kim RH, Wilson M, Mandilaras V, Berman H, Amir E, Cescon D, Elser C, Randall Armel S, McCuaig J, Volenik A, Demsky R, Chow H, Misyura M, Wang L, Oza AM, Kamel-Reid S, Stockley T, Bedard PL. Abstract P3-09-05: Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-09-05] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Variants in homologous recombination (HR) genes other than BRCA1/2 may cause a BRCA-like phenotype triple negative breast cancer (TNBC), which includes the sensitivity to platinums and DNA repair inhibitors. Evaluation of HR proficiency may influence the clinical management of TNBC. Our aim was to evaluate germline and somatic HR gene variants in advanced TNBC patients (pts) and clinical outcome.
Methods: Our cohort included advanced TNBC pts unselected for family history or age at diagnosis, enrolled in an institutional molecular screening program (NCT01505400). DNA from matched blood and FFPE tumor samples was assessed using a lab developed next generation sequencing Hereditary Cancer Panel (NGS-HCP) that includes all exons of 52 cancer predisposition genes, with 20 HR genes (Illumina MiSeq/NextSeq, germline coverage 100x, somatic coverage 500x). Medical records were reviewed for clinical outcome, pathology and prior germline BRCA1/2 testing results. All pts consented for research on banked samples and return of pathogenic germline variants was optional. Log rank test was used to determine time from surgery with curative intent to relapse (TTR) and overall survival from diagnosis to death (OS) differences based on presence of HR variants.
Results: We included 32 pts who consented for return of pathogenic germline variants and had sufficient DNA for NGS-HCP analysis. Median age at diagnosis was 45 years (range 21-80). Initial stages at diagnosis were: I (12.5%), II (62.5%), III (19%) and IV (6%). Germline HR variants were detected in 17 pts (53%) with a median number of variants per patient of 1 (range 0-6). Five pts had likely pathogenic or pathogenic variants in HR genes: BRCA1 (2), BRCA2 (1) FANCC (1) and FANCC + BML (1). Another patient had a BRCA1 pathogenic variant previously detected by Multiplex Ligation-dependent Probe Amplification but was not detected by NGS-HCP. 26 variants of unknown significance (VUS) were identified in 13 HR genes, including FANCA (6), FANCF (3) and BRCA1 (3). Only one patient had a somatic HR variant in FANCA not found in the germline. 30 pts (94%) had somatic TP53 variants. Sporadic somatic BRCA1/2 variants were not seen. BRCA1/2 variants present in the tumor were equivalent to those detected in blood of BRCA1/2 carriers. Median (m) TTR was 17 months (range 1-119) and mOS was 49 months (range 8-123). Presence of likely pathogenic or pathogenic germline variants was not associated with TTR (p=0.78) and OS (p=0.23). Presence of germline VUS, likely pathogenic or pathogenic variants also did not correlate with TTR (p=0.72) and OS (p=0.47)
Conclusions: In our cohort of pts with advanced TNBC, 12% had germline pathogenic variants in BRCA1/2, similar to the previously reported rate in early stage TNBC pts. Prevalence of likely pathogenic or pathogenic variants in non-BRCA HR genes was 6%. The presence of germline variants in HR genes was not associated with clinical outcome, however, the number of patients included was small and we had limited power to detect survival differences.Background: Variants in homologous recombination (HR) genes other than BRCA1/2 may cause a BRCA-like phenotype triple negative breast cancer (TNBC), which includes the sensitivity to platinums and DNA repair inhibitors. Evaluation of HR proficiency may influence the clinical management of TNBC. Our aim was to evaluate germline and somatic HR gene variants in advanced TNBC patients (pts) and clinical outcome.
Methods: Our cohort included advanced TNBC pts unselected for family history or age at diagnosis, enrolled in an institutional molecular screening program (NCT01505400). DNA from matched blood and FFPE tumor samples was assessed using a lab developed next generation sequencing Hereditary Cancer Panel (NGS-HCP) that includes all exons of 52 cancer predisposition genes, with 20 HR genes (Illumina MiSeq/NextSeq, germline coverage 100x, somatic coverage 500x). Medical records were reviewed for clinical outcome, pathology and prior germline BRCA1/2 testing results. All pts consented for research on banked samples and return of pathogenic germline variants was optional. Log rank test was used to determine time from surgery with curative intent to relapse (TTR) and overall survival from diagnosis to death (OS) differences based on presence of HR variants.
Results: We included 32 pts who consented for return of pathogenic germline variants and had sufficient DNA for NGS-HCP analysis. Median age at diagnosis was 45 years (range 21-80). Initial stages at diagnosis were: I (12.5%), II (62.5%), III (19%) and IV (6%). Germline HR variants were detected in 17 pts (53%) with a median number of variants per patient of 1 (range 0-6). Five pts had likely pathogenic or pathogenic variants in HR genes: BRCA1 (2), BRCA2 (1) FANCC (1) and FANCC + BML (1). Another patient had a BRCA1 pathogenic variant previously detected by Multiplex Ligation-dependent Probe Amplification but was not detected by NGS-HCP. 26 variants of unknown significance (VUS) were identified in 13 HR genes, including FANCA (6), FANCF (3) and BRCA1 (3). Only one patient had a somatic HR variant in FANCA not found in the germline. 30 pts (94%) had somatic TP53 variants. Sporadic somatic BRCA1/2 variants were not seen. BRCA1/2 variants present in the tumor were equivalent to those detected in blood of BRCA1/2 carriers. Median (m) TTR was 17 months (range 1-119) and mOS was 49 months (range 8-123). Presence of likely pathogenic or pathogenic germline variants was not associated with TTR (p=0.78) and OS (p=0.23). Presence of germline VUS, likely pathogenic or pathogenic variants also did not correlate with TTR (p=0.72) and OS (p=0.47)
Conclusions: In our cohort of pts with advanced TNBC, 12% had germline pathogenic variants in BRCA1/2, similar to the previously reported rate in early stage TNBC pts. Prevalence of likely pathogenic or pathogenic variants in non-BRCA HR genes was 6%. The presence of germline variants in HR genes was not associated with clinical outcome, however, the number of patients included was small and we had limited power to detect survival differences.
Citation Format: Stjepanovic N, Kim RH, Wilson M, Mandilaras V, Berman H, Amir E, Cescon D, Elser C, Randall Armel S, McCuaig J, Volenik A, Demsky R, Chow H, Misyura M, Wang L, Oza AM, Kamel-Reid S, Stockley T, Bedard PL. Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-09-05.
Collapse
Affiliation(s)
- N Stjepanovic
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - RH Kim
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - M Wilson
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - V Mandilaras
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - H Berman
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - E Amir
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - D Cescon
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - C Elser
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | | | - J McCuaig
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - A Volenik
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - R Demsky
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - H Chow
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - M Misyura
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - L Wang
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - AM Oza
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - S Kamel-Reid
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - T Stockley
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - PL Bedard
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| |
Collapse
|
12
|
Natori A, Ethier JL, Amir E, Cescon DW. Abstract P5-14-05: Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Capecitabine is an effective therapy for metastatic breast cancer. Its role in early breast cancer is uncertain due to conflicting data from randomized controlled trials (RCTs).
Methods
PubMed and major conference proceedings were searched to identify RCTs comparing standard chemotherapy (defined as cyclophosphamide/methotrexate/5-fluorouracil, anthracycline-based regimens or anthracycline/taxane combinations) with or without capecitabine in the neo-adjuvant or adjuvant setting. Hazard ratios (HR) for disease-free (DFS) and overall survival (OS), as well as odds ratios (ORs) for safety and tolerability were extracted or calculated and pooled in a meta-analysis. Subgroup analysis compared triple negative breast cancer (TNBC) to non-TNBC and whether capecitabine was given in addition to or in place of standard chemotherapy. Meta-regression was used to explore the influence of TNBC on OS.
Results
Eight studies comprising 9302 patients were included. In unselected patients, capecitabine did not influence DFS (HR 0.99, p=0.93) or OS (HR 0.90, p=0.36). There was a significant difference in DFS when capecitabine was given in addition to, compared to in place of standard treatment (HR 0.92 vs. 1.62, interaction p=0.002). Addition of capecitabine to standard chemotherapy was associated with significantly improved DFS in TNBC vs non-TNBC (HR 0.72 vs. 1.01, interaction p=0.02). Meta-regression confirmed this association with OS (R=-0.967, p=0.007). Capecitabine increased Grade 3/4 diarrhea (OR 2.33, p<0.001) and hand foot syndrome (OR 8.08, p<0.001), and resulted in more frequent treatment discontinuation (OR 3.80, p<0.001).
Conclusion
Adding capecitabine to standard chemotherapy appears to improve DFS and OS in TNBC, but increases adverse events in keeping with its known toxicity profile. Consideration of this treatment is warranted, especially in high-risk patients.
Citation Format: Natori A, Ethier J-L, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-14-05.
Collapse
Affiliation(s)
- A Natori
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - J-L Ethier
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - E Amir
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - DW Cescon
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| |
Collapse
|
13
|
Cescon DW, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, Rao L, Stambolic V, Sridhar S, Goodwin PJ. Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-12-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Some studies have suggested that women with high BMI have less benefit from aromatase inhibitors (AI) vs. tamoxifen as adjuvant treatment for early breast cancer. One possible mechanism for this observation is that complete suppression of estrogen is not achieved in these women with the standard flat dose of AI. We evaluated whether a doubling of letrozole to 5 mg/day for 4 weeks affected residual estrogen levels in this population.
Methods: Post-menopausal women with early breast cancer and BMI>25 already taking adjuvant letrozole for at least 3 months were recruited from medical oncology clinics at 4 sites in Toronto, Canada. Fasting blood samples were collected 24 hours following the last dose at baseline (routine use of own letrozole), after 28 days of monitored adherence to a provided supply of letrozole (Femara) 2.5 mg/day (Part A), and after an additional 28 days of letrozole (Femara) 5 mg/day (Part B). Symptom/quality of life questionnaires were completed at the same timepoints. Estradiol and estrone were measured using a high sensitivity liquid chromatography-tandem mass spectrometry assay. One interim analysis for futility and efficacy was planned after 31 eligible patients had completed the study, using estradiol and O'Brien-Fleming boundaries with an inner wedge.
Results: 36 patients were enrolled and started on study, and 31 eligible patients completed Parts A and B. The 5 non-completers withdrew because of adverse events (n=4, unlikely related to drug) or withdrawal of consent (n=1). Median age was 62 (range 48 to 77) and BMI 28.3 kg/m2 (Range 25.2 to 42.2 kg/m2). One patient had non-postmenopausal estrogen levels at Day 29 and Day 57 and one patient's blood assay was unsuccessful; both were excluded from further analyses. The predetermined stopping rule for futility was met. Estradiol levels (mean±standard deviation) changed from 2.68±0.40 pg/mL at baseline to 2.67±0.59 pg/mL at Day 29 to 2.70±0.53 pg/mL at Day 57. Mean change from Day 29 to Day 57 was 0.03±0.48 pg/mL (95% confidence interval -0.15 to 0.21 pg/mL). Four patients reported new or increased arthralgias (to NCI CTCAE Grade 2 or 3) while taking letrozole 5 mg/day in Part B. There was no association between changes in estradiol levels and either study non-completion or the development of arthralgias. Estrone results were similar.
Conclusion: Increasing letrozole from 2.5 to 5 mg/day did not further suppress estrogen levels in women with BMI>25. It is unlikely that letrozole dosing tailored to body size would improve clinical outcomes. The letrozole 5 mg/day intervention was terminated based on the results of the interim analysis for futility.
Citation Format: Cescon DW, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, Rao L, Stambolic V, Sridhar S, Goodwin PJ. Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-12-02.
Collapse
Affiliation(s)
- DW Cescon
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - M Ennis
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Townsley
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - D Warr
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - C Elser
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - L Rao
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - V Stambolic
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - S Sridhar
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| | - PJ Goodwin
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, ON, Canada; Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada
| |
Collapse
|
14
|
Cescon DW, Ganz PA, Hallak S, Ennis M, Mills BK, Goodwin PJ. Abstract P5-13-09: Feasibility of a Randomized Controlled Trial of Vitamin D vs. Placebo in Recently Diagnosed Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-13-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Vitamin D (Vit D) supplementation is an area of interest in the primary and secondary prevention of many cancers. We previously reported a high prevalence of Vit D insufficiency and deficiency in newly diagnosed breast cancer (BC) patients. Low Vit D levels were associated with poor BC outcomes. Here we evaluate the state of Vit D adequacy and supplementation in a more recently diagnosed cohort of BC patients from 2 large urban centres, and we examine the feasibility of a placebo-controlled randomized trial (RCT) of supplementation in this population. Patients and Methods: Women diagnosed with T1-3, N0-3, M0 invasive BC within the previous 2 years were prospectively identified from institutional registries and recruited from Mount Sinai Hospital, Toronto and UCLA, Los Angeles (LA), between March 2009 and January 2010. Anthropometric measurements were performed, and dietary, lifestyle and medication histories were obtained using structured questionnaires and interviews. Tumor and treatment characteristics were obtained from clinical records; blood samples were collected for analysis of Vit D levels. The pre-specified feasibility criteria for a Vit D (vs placebo) RCT were: ≥30% of patients with (i) deficient or insufficient Vit D levels, (ii) taking ≥1000 IU Vit D/day and (iii) willing to participate in such a trial.
Results: 173 eligible patients were enrolled (80 Toronto, 93 LA). Median age at enrollment was 57 years; 73.4% were post-menopausal. Median tumor size (1.8 cm), lymph node involvement (39%), ER (80%), PR (65%) and Her2 (15%) positivity were similar between centres. Treatment characteristics including rates of mastectomy (44%), adjuvant chemotherapy (56%), radiation (68%), hormonal therapy (69%) and trastuzumab (14%) did not differ between centres. 84.4% of women reported use of Vit D containing supplements, with median daily doses of 1200 IU (Toronto) and 1400 IU (LA) (p=0.3) among users. Respective median 25-OH Vit D levels were 85.5 nmol/L (34.3 ng/mL) and 98.5 nmol/L (39.5 ng/mL) (p=0.04), and rates of deficiency, insufficiency and adequacy were 3.8%, 23.8%, 72.5% (Toronto) and 4.3%, 20.7%, 75.0% (LA) (p=0.88). No Vit D levels were in the toxic range. 25-OH Vit D levels correlated with Vit D supplement use (r=0.41, P<0.0001). 68% of women expressed willingness to participate in a Vit D RCT; however, only 12.7% of the study population met the pre-specified feasibility criteria.
Conclusions: Vit D levels and supplementation rates are substantially higher in these BC patients than in previous cohorts, though more than 25% of women do not have adequate levels. Rates of adequacy did not
differ between patients recruited in Toronto and LA. While the maj ority of women would be willing to participate in an RCT of Vit D supplementation, low levels of deficiency/insufficiency and high rates of supplement use may limit the feasibility of such a study. Funded by the Breast Cancer Research Foundation.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-13-09.
Collapse
Affiliation(s)
- DW Cescon
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - PA Ganz
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - S Hallak
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - M Ennis
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - BK Mills
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| | - PJ. Goodwin
- Mount Sinai and Princess Margaret Hospitals, University of Toronto, ON, Canada; Jonsson Comprehensive Cancer Center, UCLA Schools of Medicine & Public Health, Los Angeles, CA
| |
Collapse
|